News and Announcements
Imugene CEO Presents in U.S and Australia & Four New Patent Applications
- Published March 14, 2017 12:00AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
Imugene Limited has recently released their first quarter 2017 update on their current achievements.
KEY TAKEAWAYS:
- Leslie Chong presented on Feb 13, 2017 at “Wall Street Wonders” in New York, NY.
- The role of all contributors was to share their own views and experience to help inform insightful content, while supporting their own thought leadership/ profile building. Leslie was invited to share her views and perspectives on the future of Australian business and the characteristics businesses require for success beyond tomorrow.
- 9 March 2017: Leslie Chong presented at the “Sydney Small Cap Showcase” for Wholesale Investor.
- CEO, Leslie Chong has received great kudos and acknowledgement on her efforts to bring Imugene into the foreground of immuno- oncology research and development.
- 2016 was a busy foundation year for our new Mimotope Program. It ended well with our filing of four new patent applications with IP Australia. Three of the patents filed specifically to protect new mimotope B-cell vaccine compositions which are directed to commercially validated immuno-oncology targets.
Company Updates
500 Million Episodes, Limited Treatment: How Patrys is Bridging the Gap in an Underserved Market
In the clinical vocabulary of the Intensive Care Unit, there is perhaps no word that carries as much quiet dread as delirium. It is a “chemical storm” of the brain—an acute dysfunction where the delicate balance between calming and activating signals is scrambled. For the patient, it can be a waking nightmare of hallucinations and […]
The Light Fantastic: Why Invion’s Photodynamic Therapy May Be Attracting Big Pharma’s Attention
Invion Limited is challenging the status quo in oncology with its Photosoft™ platform, a precision therapy that uses light-activated molecules to selectively target cancer cells. By transforming the body’s own immune response and addressing the high costs of current cancer treatments, Invion is positioning itself as a transformative player in the biotech sector. With clinical trials underway and strong institutional partnerships, the company is bridging the gap between scientific breakthrough and accessible, scalable patient care.
From Outback to Boardroom: How SWAN Systems is Codifying Water Stewardship
From the arid deserts of Australia to the boardrooms of global tech giants, SWAN Systems is redefining water efficiency. By bridging the gap between field-level agronomics and autonomous irrigation control, the company is proving that “water-positive” targets can be met with science, data, and a 10x ROI commitment.
Backed By Leading Investment Groups and Family Offices
